Pharmacodynamic of cyclooxygenase inhibitors in humans
- 31 January 2007
- journal article
- review article
- Published by Elsevier BV in Prostaglandins & Other Lipid Mediators
- Vol. 82 (1-4), 85-94
- https://doi.org/10.1016/j.prostaglandins.2006.05.019
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJCI Insight, 2005
- Pharmacokinetic–pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitorsRheumatology, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and InhibitionPharmacological Reviews, 2004
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialThe Lancet, 2004
- COX-2 and beyond: approaches to prostaglandin inhibition in human diseaseNature Reviews Drug Discovery, 2003
- Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2003
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000